VACH — Voyager Acquisition Corp. Stock Price, Chart & AI Report

Neutral Sep 30, 2025 • 12:00 UTC GlobeNewswire Inc. • Not Specified

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

VERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for treating autoimmune and chronic immune diseases, combining their unique technology platforms.

VACH VACHU VACHW antibody oligonucleotide conjugates immunology therapeutic development gene expression targeted therapy

Sentiment note

Facilitating potential business combination with VERAXA Biotech without direct involvement in the research collaboration

Positive May 29, 2025 • 22:34 UTC GlobeNewswire Inc. • N/A

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Biotech, an emerging leader in cancer therapies, is attending the ASCO and BIO conferences to showcase its BiTAC platform and meet with potential partners and investors. The company is preparing to list on the NASDAQ later this year.

VACH VACHU VACHW VERAXA Biotech Voyager Acquisition Corp. Cantor Fitzgerald BiTAC platform cancer therapies

Sentiment note

Voyager Acquisition Corp. is described as the proposed de-SPAC acquisition target for VERAXA Biotech, suggesting a positive outlook for the potential business combination and Voyager's involvement in VERAXA's growth.

Neutral May 5, 2025 • 16:59 UTC GlobeNewswire Inc. • N/A

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.

OABI OABIW VACH VACHU bispecific antibody drug conjugate solid tumors ADC technology antibody discovery

Sentiment note

The article mentions Voyager Acquisition Corp. as the proposed acquirer of VERAXA Biotech, but the focus of the article is on the co-discovery alliance between VERAXA and OmniAb, rather than the acquisition.